Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 33004, Taiwan
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan
Research Department of Practice and Policy, UCL School of Pharmacy, London WC1N 1AX, UK
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan
Cancer Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97002, Taiwan
College of Medicine, Tzu Chi University, Hualien 97004, Taiwan
Department of Urology, Keelung Chang Gung Memorial Hospital, Keelung 20401, Taiwan
Author to whom correspondence should be addressed.
Academic Editor: Vasiliki Tzelepi
Received: 21 June 2021
Revised: 26 July 2021
Accepted: 27 July 2021
Published: 31 July 2021
Androgen deprivation therapy (ADT) is the gold standard treatment for advanced prostate cancer and the subsequent risk of dementia remains controversial. Previous studies were limited by small sample sizes, short follow-up times, and racial differences. In this population-based cohort study, we used the National Health Insurance Database of Taiwan and The Health Improvement Network database of the United Kingdom to retrospectively study 129,126 men with prostate cancer in the United Kingdom (UK) and Taiwan. Compared with the ADT-naïve control, patients treated with ADT showed no significant increase in the risk of dementia in both the UK and Taiwan populations. Despite the differences in the populations of the two databases, these results suggest no association between the use of ADT and new-onset dementia.